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Education and debate
Problems with UK government’s risk sharing scheme for
assessing drugs for multiple sclerosis
Cathie L M Sudlow, Carl E Counsell
The government plans to make interferon beta and glatiramer available to patients with multiple
sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and
colleagues argue that the money would be better spent on independent research
The National Institute for Clinical Excellence (NICE)
recently announced that interferon beta and glati›
ramer acetate were not cost effective treatments for
multiple sclerosis and could not be recommended for
NHS funding.1 As a result, the Department of Health
and the manufacturers developed a “risk sharing
scheme” aimed at providing these drugs more cost
effectively.2 3 Treatment will be provided to ambulating
patients with two or more disabling relapses in the past
two years (about 15% of all patients with multiple scle›
rosis)4 and their progress monitored over 10 years.
However, the scheme has several scientific and
practical problems that we believe limit its ability to
improve the care of patients in the long term. In this
paper, we review the quality of the evidence on which
NICE and the Department of Health reached their
decisions, consider some of the problems of the risk
sharing scheme, and suggest an alternative approach.
Methods
We identified randomised trials of disease modifying
drugs in patients with multiple sclerosis from
systematic reviews,5–7 the Cochrane controlled trials
register, and the treatment guidelines of the Associ›
ation of British Neurologists.4 We also got information
from discussion with colleagues, including several
international experts in multiple sclerosis. We used
Cochrane RevMan software to produce summary rela›
tive risks.
What is the evidence that the drugs are
effective?
NICE considered data from placebo controlled trials of
interferon beta and glatiramer acetate but did not
assess azathioprine, which has also been widely tested
in multiple sclerosis.5–31 The three drugs produce a
similar reduction (15›30%) in the relative risk of a
relapse at two years (fig 1). Interferon beta and
glatiramer may also reduce disability (fig 2), but appro›
priate data were not available for azathioprine.
Although interferon beta, glatiramer, and azathioprine
were all associated with more patient withdrawals than
placebo, the side effects were generally mild. Azathio›
prine may be associated with a small increased risk of
neoplasia after 10 years of treatment,32 33 but there is
not enough long term experience with either
interferon beta or glatiramer to exclude an increased
risk of cancer.
These results, although promising, are based on
limited, short term data (a few hundred patients for
each drug, usually followed up for no more than two
years). We therefore do not know whether the effects
are sustained over the long term. Several other
previously noted methodological problems7 also limit
the interpretation of the results and may have biased
them in favour of active treatment. These include
uncertainty about the adequacy of randomisation,34
which is not always clearly described; unavoidable
patient unblinding35; difficulty interpreting the out›
come of confirmed progression of disability, which was
generally based on the widely criticised expanded dis›
ability status score36 37; substantial losses to follow up in
a few trials; publication bias (the largest randomised
trial assessing interferon beta in secondary progressive
multiple sclerosis showed no overall effect on progres›
Summary points
NICE has announced that neither interferon beta
nor glatiramer can be recommended for multiple
sclerosis in the NHS
The Department of Health plans to make these
drugs available through a risk sharing scheme
that is scientifically unsound and impractical
Randomised trials suggest that azathioprine (which
is 20 times cheaper) may be just as effective
The long term effectiveness of these drugs is
unknown
Government money would be better spent on a
long term randomised trial comparing interferon
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sion of disability but remains unpublished17); and fund›
ing of the trials by pharmaceutical companies, which
own the data and were involved in the trials’ design,
conduct, analysis, and reporting.9–24Although many
trials had independent data monitoring committees, it
is concerning that some data from some trials have not
been placed in the public domain.
Limitations of NICE’s assessment of
cost effectiveness
NICE’s conclusions on cost effectiveness were based
mainly on an analysis commissioned from the Sheffield
University School of Health and Related Research.1 38
The researchers calculated the cost per quality
adjusted life year (QALY) gained at 5, 10, and 20 years
after starting treatment (table). The model suggests
that the threshold of £36 000 per QALY (set by the
Department of Health for the risk sharing scheme) is
approached only after 20 years.
Although this economic model is probably the best
available for multiple sclerosis, it has several unavoid›
able flaws. Firstly, it depends on the quality of the
evidence for effectiveness of treatment, which, as high›
lighted above, has major deficiencies. Treatment effects
were estimated mainly from published reports. Two
companies provided some additional confidential data,
one refused, and one withdrew its additional data after
seeing its effects on the results.1 38
Secondly, because of the lack of long term placebo
controlled randomised trials, the model compares the
effects of treatment with the experience of a cohort of
1000 Canadian patients with multiple sclerosis
recruited in the 1970s and 1980s and followed for an
average of 25 years.39 40 It assumes that treatment
remains effective for as long as the patient takes it and
that the benefit accrued is maintained after treatment
stops. NICE acknowledges that this extrapolation of
treatment effects becomes increasingly unreliable as
the time horizon is increased.1 38
Thirdly, the model is heavily influenced by assump›
tions about future discounting of costs and benefits, the
proportion of patients who stop treatment prema›
turely and what happens to them, and the way in which
the costs of disability related to multiple sclerosis are
estimated (table).38 Finally, it does not consider azathio›
Fig 1 Risk of relapse of multiple sclerosis at about two years. Numbers were obtained from a systematic review of interferon beta in
relapsing›remitting multiple sclerosis5 as well as individual trials. There was no statistical heterogeneity between individual trials contributing to
summary statistics
Fig 2 Risk of progression of disability at about two years. Numbers were obtained from a systematic review of interferon beta in
relapsing›remitting multiple sclerosis5 as well as individual trials. There was no statistical heterogeneity between individual trials contributing to
summary statistics
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prine, which has an annual treatment cost of only
about £300 a patient.
Scientific flaws of risk sharing scheme
The risk sharing scheme plans to use the Sheffield
model as a basis for assessing and adjusting the real
life cost effectiveness of interferon beta and glatiramer.
Azathioprine has been ignored. Patients meeting the
Association of British Neurologists treatment criteria4
will be assessed annually for 10 years to determine the
rate of progression from no disability (expanded
disability status score < 4), through mild (4›5.5) and
moderate (6›6.5), to severe disability (>7). The effects
of each treatment will be determined every two years
by comparison with the expected progression without
treatment derived from the Canadian cohort.3 39 40
Target treatment effects have been agreed with the
drug companies, and if these are not achieved, the
drug costs will be reduced to maintain cost
effectiveness at a threshold of £36 000 per QALY over
20 years.3 Unfortunately, the scheme has several major
problems.
Non›randomised comparisons
The Department of Health circular states that the
scheme is not a further trial of clinical effectiveness but
a study to establish long term cost effectiveness.3 How›
ever, a reliable estimate of long term cost effectiveness
first requires a reliable estimate of long term clinical
effectiveness. This will not be achieved by comparing a
modern cohort of patients treated in the United King›
dom with a historical cohort of Canadian patients
since non›randomised comparisons give unreliable,
biased results.41 42
Lack of power calculations
The scheme will include about 7000 patients in
England and Wales (plus more patients from
Scotland), but the circular gives no power calculations
to justify this number.3 It recognises that the
non›randomised comparison will be biased and that
chance may lead to imprecise measures of treatment
effect. However, rather than randomising large
numbers of patients, the Department of Health
proposes to incorporate a tolerance margin of 10›20%
in the comparison between the treated and untreated
cohorts.3 It does not explain how this margin was cho›
sen; nor is it clear whether the margin represents a
relative or absolute difference in outcome.
Other biases
The risk sharing scheme is subject to several other
biases. Firstly, patients already receiving treatment at
the start of the scheme will be included if they fulfilled
the inclusion criteria at the start of treatment and their
pre›treatment disability score and other prognostic
data are available.3 This will bias the comparison in
favour of treatment because patients who started and
then stopped treatment before the scheme because of
adverse effects or perceived lack of effectiveness will
not be included.
Secondly, the circular states that patients who stop
taking treatment during the scheme are “to be
monitored as far as possible.”3 This is not good
enough. It is essential to follow up such patients
because we do not know how patients respond once
they stop treatment. This information is critical to the
cost effectiveness calculations.
Thirdly, the scheme does not intend to have
blinded assessment of outcome. Unblinded assessment
of outcome in multiple sclerosis trials can result in
overestimates of the effect of treatment on progression
of disease.35 Hence, an apparent treatment benefit may
simply be due to the expectation bias of patients and
their neurologists or specialist nurses. An additional
competing interest bias may be introduced by
unblinded assessment of outcome being done by
specialist nurses whose salaries are paid for by
pharmaceutical companies.
Calculation of cost effectiveness
The estimates of cost effectiveness depend critically on
the various assumptions used in the modelling process,
but the actual assumptions to be used are not
mentioned in the circular. These will have to be made
explicit and justified before the scheme starts.3
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Published plus confidential commercial data‡
20 years 10 years 5 years
Intramuscular interferon
beta›1›a11 12
Relapsing›remitting 9 061 0.82 0.54 48 000 106 000 618 000 783 000
Subcutaneous interferon
beta›1›a 22 ìg13
Relapsing›remitting 9 088 0.71 0.64 59 000 59 000 325 000 511 000
Subcutaneous interferon
beta›1›a 44 ìg13
Relapsing›remitting 12 068 0.67 0.62 79 000 79 000 406 000 638 000
Subcutaneous interferon
beta›1›b 8 MIU9 10





7 259 0.69 0.72 41 000 43 000 230 000 380 000
Subcutaneous glatiramer21 22 Relapsing›remitting 6 650 0.71 0.76 98 000 98 000 442 000 443 000
* This assumes that patients are treated according to the Association of British Neurologists criteria for starting and stopping treatment; the mean age of patients at the start of treatment is 30
years; costs are discounted at 6% per year and quality of life benefits at 1.5% per year; 10% of patients will withdraw from treatment during each of the first two years and 3% per year
thereafter. The model allows for variation in these assumptions, in the costs and treatment effects shown in the table above and in other factors (costs of multiple sclerosis related disability and
relapses, and the utilities associated with various disability states, relapses, and treatment side effects). Some important examples are: (a) if the discount rate for future benefits is increased
from 1.5% to 6% annually, the costs per QALY gained roughly double; (b) if the model assumes that nobody stops treatment prematurely, the costs per QALY gained increase further by up to a
third.
†Costs are those quoted in the NICE and Sheffield reports and used in the cost effectiveness analyses summarised here. Note that for the risk sharing scheme, the Department of Health has
stated that the annual costs are interferon beta›1›a £8502, interferon beta›1›a 22 ìg £7513, Interferon beta›1›a 44 ìg £8942, interferon beta›1›b 8 MIU £7259, glatiramer £5823.
‡Additional data were available from only Biogen11 12 and Schering.9 10 15 The nature of these data is not clear from the Sheffield report.
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Other issues
The circular does not state what will happen if a treat›
ment seems ineffective. Neither does it tell us which
patients will be included in the analyses or whether
these will be on a truly intention to treat basis. Ideally, a
proper intention to treat analysis would be ensured by
information on patients giving their consent being
telephoned or faxed immediately to a central site. This
would avoid the loss or non›registration of patients
who do not do well on their chosen treatment.
However, no details of this sort have been provided.
Practical problems with risk sharing
scheme
The Department of Health proposed that patient
recruitment would start on 6 May 2002. However,
the national coordinating team was not appointed
until July 2002, ethical approval has had to be sought,
and many neurologists have yet to see a detailed
protocol.
The cost of the drugs (more than £50m a year) for
the scheme will have to be met from existing NHS
budgets. In addition, collecting data is likely to put fur›
ther strain on NHS resources. The circular states that
“the scheme should as far as possible build on normal
clinical practice without requiring elaborate additional
infrastructure” and that “data entry should be as simple
as possible and arise out of normal patient contacts.”3
However, neurological services are already extremely
stretched (median outpatient waiting times are about
26 weeks), and many potentially eligible patients do
not have regular contact with a neurologist.43 Many
additional consultant neurology and specialist nurse
sessions (with appropriate administrative support) will
be needed to evaluate patients who may be eligible and
to follow up those who join the scheme. Normal
patient contacts do not include assessment of the
expanded disability status score, and so appointments
will have to be longer to allow for this. It is not clear
how all these additional sessions can be provided with›
out seriously compromising the existing service,
although the pharmaceutical companies will fund
some. Local staff (probably specialist nurses) will need
to be trained to collect, store, and transfer the
additional data.
Alternative proposal
We believe that the government could spend the extra
resources for patients with multiple sclerosis more
effectively. Firstly, it should commission an independ›
ent, individual patient data overview of all relevant
published and unpublished randomised trials of
disease modifying drugs for multiple sclerosis. The
overview would address unanswered questions about
the trials and may go some way towards resolving the
uncertainties about the effects of interferon beta, glati›
ramer, and azathioprine.
Secondly, the risk sharing scheme should be modi›
fied to include a concurrent, randomised control group
rather than a historical cohort. Given that the Depart›
ment of Health is committed to providing resources
for the assessment, long term follow up, and drug costs
for several thousand patients with multiple sclerosis, a
long term randomised trial, run independently of the
pharmaceutical industry, would be a far more scientifi›
cally (and so ethically) justifiable use of this money.
Patients could be randomised three ways (interferon
beta or glatiramer versus azathioprine versus no treat›
ment) and followed up in the same manner and with
the same outcomes as the existing scheme. Additional
resources would be required for blinded outcome
assessment and perhaps inclusion of a quality of life
outcome, but a trial would probably be less expensive
than the present scheme because only one third of
patients would be taking an expensive drug. Careful
explanation would have to be given to patient groups
about why a randomised trial is the best way forward as
fewer patients would be receiving active treatment.
However, it is the patients who have most to gain by
reliably establishing the long term clinical effectiveness
as well as cost effectiveness of these treatments.
Conclusions
Any additional resources for patients with multiple
sclerosis are welcome. However, these should be used
to provide services that we know benefit patients and to
support further, properly designed research into inter›
ventions about which there is still uncertainty.
Uncertainty remains about the effectiveness and cost
effectiveness of interferon beta and glatiramer, and the
risk sharing scheme will neither resolve these nor
determine the possible role of promising but far less
expensive drugs such as azathioprine. All patients with
multiple sclerosis, whether eligible for treatment under
the terms of the scheme or not, deserve much better
than this. The government should consider a more
appropriate use of this large amount of public money.
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When I use a word
Wholly, holy, holey
The Greek word ï‘′ëïò (holos) means entire or whole. Now you
might think that the English word whole has the same origin, but
you would be wrong.
The Greek ï‘′ëïò comes from an Indo›European root SOLO,
meaning whole, firm, sound, or correct. A holograph is written
entirely in one’s own hand, and a holocaust was originally the
burning of a whole body, before it came to mean the destruction
of a whole nation. Catholic (from the Greek êáôá, throughout)
means throughout the whole world. SOLO also gives solicitous
(wholly concerned with something), solemn (wholly religious),
and solid. The old Roman coin the solidus was considered to be
wholly reliable, and a soldier was one who was paid in solidi.
Solidago is the genus of plants including goldenrod, once
thought to be a panacea (making people whole), and solipeds are
ungulates with uncloven hooves.
Whole, on the other hand, has a different Indo›European root,
KAILO, of good omen or unharmed. A celibate was originally
someone who was healthy (specifically, free from sexually
transmitted diseases) and later someone who lived alone. The
names Helga, Olga, and HØloise come from the same root, as
does holy. Someone who is hale is healthy and whole. And the
greeting “Hail” is short for “Be healthy.”
The homophone hole comes from yet another Indo›European
root, KEL, a hollow or to cover or hide. The goddess Calypso hid
Odysseus on her island for seven years, delaying his return to
Ithaca. The Eucalyptus is well covered, having caps over its buds.
The Apocalypse has come from under cover and is therefore
apparent in the Book of Revelations. And colours cover the surface
of things, hiding them. Hell is a hole in the ground, and Hel was
the Norse goddess of the dead. Hollow structures include a hall, a
holster, a helmet, and the hull of a boat or the hull or husk of corn.
In 1926 the South African statesman General Jan Christian
Smuts invented the concept of holism—defined in the Oxford
English Dictionary as “the tendency in nature to produce wholes
from the ordered grouping of unit structures”—which, Smuts said,
“is seen at all stages of existence.” Then in the 1930s the idea of
wholism was invented as a sort of pun on holism, and defined as
“the doctrine or belief that wholes must be studied as such.”
Nowadays these two ideas have been confounded, and we talk
about holistic medicine, when what we really mean is wholistic
medicine.
And that’s the whole truth.
Jeff Aronson clinical pharmacologist, Oxford
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